Altimmune (LTS:0A4C) Current Accrued Expense : $8.48 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Altimmune Current Accrued Expense?

Altimmune's Current Accrued Expense for the quarter that ended in Mar. 2025 was $8.48 Mil.

Altimmune's quarterly Current Accrued Expense increased from Sep. 2024 ($7.19 Mil) to Dec. 2024 ($9.98 Mil) but then declined from Dec. 2024 ($9.98 Mil) to Mar. 2025 ($8.48 Mil).

Altimmune's annual Current Accrued Expense declined from Dec. 2022 ($10.63 Mil) to Dec. 2023 ($9.58 Mil) but then increased from Dec. 2023 ($9.58 Mil) to Dec. 2024 ($9.98 Mil).

Altimmune Current Accrued Expense Historical Data

The historical data trend for Altimmune's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Current Accrued Expense Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

11.05

9.74

10.63

9.58

9.98

Altimmune Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															7.07	12.12	7.19	9.98	8.48

Altimmune Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Altimmune Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Altimmune's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALT:USA 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines